Avstera Therapeutics Announces FDA Clearance of IND Application for AVS100, a Novel Highly Selective HDAC6 Inhibitor Targeting Solid Tumors
Retrieved on:
Monday, December 18, 2023
Georgetown University, Tumor-associated macrophage, AMES, Research, GLP, Safety, Therapy, Incidence, RECIST, Toxicology, IND, Risk, Macrophage, Patient, FIH, PFS, MD Anderson Cancer Center, U.S. FDA, FDA, Pembrolizumab, Animal, ICB, SAB, Pharmacokinetics, Marketing, Investigational New Drug, FAAAS, Progression-free survival, ORR, MD, Cancer, MTD, Phase, Doctor of Philosophy, HDAC6, Biomarker, Infrared spectroscopy correlation table, Immunotherapy, Coronavirus Scientific Advisory Board, Neoplasm, Rat, Dog, Government, Pharmaceutical industry, Medicine
AVS100 is a novel, orally bioavailable selective HDAC6i targeting locally advanced or metastatic solid tumors, including in combination with pembrolizumab.
Key Points:
- AVS100 is a novel, orally bioavailable selective HDAC6i targeting locally advanced or metastatic solid tumors, including in combination with pembrolizumab.
- "The FDA clearance of our IND for AVS100 marks an amazing step for our company towards the fulfillment of our mission.
- "FDA clearance of our IND for AVS100 represents a significant milestone for Avstera's mission in providing state of the art oncological agents to tackle solid tumors.
- Undoubtedly, the IND approval of AVS100 selective HDAC6 inhibitor will open new opportunities to potentially enhance response rates for patients."